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ORIGINAL STUDIES
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Abstract
Background: Description of procedural outcomes using contemporary techniques that
apply specialized coronary guidewires, microcatheters, and guide catheter extensions
designed for chronic total occlusion (CTO) percutaneous revascularization is limited.
Methods: A prospective, multicenter, single-arm study was conducted to evaluate
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procedural and in-hospital outcomes among 150 patients undergoing attempted
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CTO revascularization utilizing specialized guidewires, microcatheters and guide
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extensions. The primary endpoint was defined as successful guidewire recanalization
and absence of in-hospital cardiac death, myocardial infarction (MI), or repeat target
lesion revascularization (major adverse cardiac events, MACE).
Results: The prevalence of diabetes was 32.7%; prior MI, 48.0%; and previous bypass
surgery, 32.7%. Average (mean ± standard deviation) CTO length was 46.9 ± 20.5 mm,
and mean J-CTO score was 1.9 ± 0.9. Combined radial and femoral arterial access was
performed in 50.0% of cases. Device utilization included: support microcatheter, 100%;
guide catheter extension, 64.0%; and mean number of study guidewires/procedure
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was 4.8 ± 2.6. Overall, procedural success was achieved in 75.3% of patients. The rate
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of successful guidewire recanalization was 94.7%, and in-hospital MACE was 19.3%.

Torrance Memorial Medical Center,
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Achievement of TIMI grade 2 or 3 flow was observed in 93.3% of patients. Crossing
strategies included antegrade (54.0%), retrograde (1.3%) and combined antegrade/

Yale Cardiovascular Research Group,
New Haven, Connecticut, USA

retrograde techniques (44.7%). Clinically significant perforation resulting in hemody-
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namic instability and/or requiring intervention occurred in 16 (10.7%) patients.

Teleflex, Inc., Minneapolis, Minnesota, USA

Abbreviations: CTO, chronic total occlusion; MACE, major adverse cardiac event; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial
Infarction; TLR, target lesion revascularization.
Clinical Trial Registration: NCT03988166
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Conclusions: In a multicenter, prospective registration study, favorable procedural
success was achieved despite high lesion complexity using antegrade and retrograde
guidewire maneuvers and with acceptable safety, yet with comparably higher risk
than conventional non-CTO PCI.
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and in-hospital outcomes among patients undergoing attempted CTO
PCI at 13 investigational centers in the United States (US). The study

Against the background of increasing complexity in percutaneous cor-

was designed with guidance from the US Food and Drug administra-

onary intervention (PCI) and paralleled by advancement in procedural

tion (FDA) and was intended to support US device approval. Eligible

technique, chronic total occlusion (CTO) revascularization persists

patients provided written informed consent prior to the interventional

among lesion complexities with the highest rates of procedural failure.

procedure. Eligible patients were aged 18 years or older with symp-

Despite a marked escalation in attempted CTO PCI over recent years,

tomatic ischemic heart disease undergoing elective, clinically indicated

rates of procedural success have only modestly improved, and

percutaneous recanalization of a de novo occlusive coronary lesion

procedural-related safety has at best plateaued, if not worsened.1–5

exhibiting Thrombolysis in Myocardial Infarction (TIMI) grade 0 or

Aside from predictive models to inform procedural outcome, fac-

1 flow and estimated to be at least 3 months duration by clinical his-

tors commonly associated with improvements in CTO success include

tory and/or comparison with a prior angiogram or electrocardiogra-

5,6

and the application of enabling strategies that

phy. Consented patients were considered enrolled upon advancement

incorporate not only advanced technique but also device technologies

of a study device within the guide catheter. Angiographic exclusion

that include purpose-built guidewires, microcatheters and guide cathe-

criteria were in-stent total occlusions, proximal disease (> 75% steno-

ter extensions.2,7 Unlike conventional coronary guidewires, for example,

sis) that cannot be treated with a stent that also is intended for the

contemporary development of CTO-specific guidewire design enables

target CTO lesion, and extensive lesion-related thrombus. Principal

penetration of fibrous and calcified proximal cap disease, navigation

clinical exclusion criteria were recent (< 72 h) myocardial infarction

through microchannels or subintimal planes and luminal re-entry. Simi-

(MI), prior interventional procedure of any kind within 30 days of the

larly, specialized microcatheters are constructed to permit guidewire

index procedure or any general contraindication to the revasculariza-

crossing penetrability, permit guidewire exchange or traverse collateral

tion procedure and routine pharmacologic therapies. There were no

channels. Guide catheter extensions provide not only advanced support

restrictions regarding ejection fraction, lesion length, or treatment

for guidewire crossing but also enable device delivery and exchange,

strategy (e.g., antegrade, retrograde, wire escalation, or dissection re-

and in some instances facilitate retrograde guidewire recanalization.

entry technique). The study was approved by the institutional review

operator experience

Despite their common use in CTO PCI, relatively few studies have

board at each site.

detailed procedural outcomes and technique related to CTO-specific
guidewires, microcatheters and guide catheter extensions among
patients undergoing attempted revascularization.7,8 Further, many of
these commonly used devices do not have formal regulatory approval

2.2 | Device description and interventional
procedure

for this specific clinical indication. We performed a prospective, multicenter registration study to evaluate procedural and in-hospital out-

The investigational devices used in this study included guidewires,

comes among patients undergoing attempted CTO PCI using

microcatheters, and guide catheter extensions. Per protocol, use of at

specialized coronary guidewires, microcatheters and guide catheter

least one study guidewire and microcatheter was mandated, and utili-

extensions to inform CTO procedural technique and strategy.

zation of a guide extension catheter was permitted according to operator discretion. Study guidewires included Spectre (nitinol and
stainless steel), Raider (stainless steel, polymer jacket), Warrior (stain-

2
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less steel, 0.009 inch diameter tapered distal tip), Bandit (stainless
steel, polymer jacket, 0.008 inch diameter tapered distal tip), and

2.1

|

Study design and population

R350 (externalization guidewire). The investigational microcatheters
were Turnpike, Turnpike LP, Turnpike Spiral, and Turnpike Gold.

The Teleflex Chronic Total Occlusion Study (Vascular Solutions/Tele-

Details regarding guidewire dimensions, construction and tip load and

flex, Inc., Minneapolis, MN; clinicaltrials.gov identifier NCT03988166)

microcatheter design are provided in the Appendix. Rapid-exchange

was a prospective, single-arm, multicenter study examining procedural

guide extensions evaluated in the study were the GuideLiner and

3
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TrapLiner catheters (Appendix). The TrapLiner catheter incorporates a
trapping balloon on the distal end of the pushrod to facilitate device
exchange over a guidewire. The intended purposes of the study

TABLE 1

Study devices and general purpose

Study device

Category

GuideLiner

Guide extension Use in conjunction with guide
catheters to facilitate
deliverability and placement of
interventional devices; provide
device/catheter support;
facilitate retrograde wire reentry

TrapLiner

Guide extension Same purposes as GuideLiner but
has an inflatable balloon on the
distal shaft to facilitate the
exchange of interventional
devices while maintaining the
position of a guidewire within
the vasculature

Turnpike

Microcatheter

Used to access discrete regions of
the coronary artery anatomy;
increase guidwire crossing
penetrability; traverse collateral
channels; facilitate placement
and exchange of guidewires;
and infuse/deliver diagnostic
and therapeutic agents

Turnpike LP

Microcatheter

Same purposes as Turnpike but
has a lower profile and
increased flexibility

guidewires, microcatheters and guide catheter extensions are summarized in Table 1.
Procedural methods and technique were performed according to
the investigator's discretion. Specifically, there were no protocol
criteria related to procedural methods other than exclusion of planned
target lesion treatment with a device other than balloon angioplasty
and stent placement after successful guidewire crossing (i.e., planned
use of atherectomy was excluded). Prior to PCI, all patients received
treatment with aspirin (100–325 mg) and either clopidogrel, ticagrelor,
or prasugrel per investigator discretion. For patients not receiving
chronic P2Y12 receptor or ADP receptor antagonist therapy, a loading
dose was administered according to individual product labeling. Dual
anti-platelet therapy was prescribed per investigator discretion. Procedural anticoagulation with unfractionated heparin was recommended
to achieve an activated clotting time >250 s, and treatment with a glycoprotein IIb/IIIa inhibitor was discouraged. All lesions were treated
with commercially available drug-eluting stents.

2.3

|

Study endpoints and definitions

The primary endpoint was procedural success, defined as angiographic

Turnpike Spiral Microcatheter

Same purposes as Turnpike but
has an added outer coil on the
distal shaft for additional
rotational advancement

Turnpike Gold

Microcatheter

Same purposes as Turnpike but
with an added outer coil on the
distal shaft and a gold-plated
stainless steel, threaded distal
tip for additional rotational
advancement in resistant
lesions

Spectre

Guidewire

0.01400 all-purpose, workhorse
guidewire

Raider

Guidewire

0.01400 polymer-jacketed
guidewire to facilitate
penetration of fibrous and
calcified proximal cap disease,
navigation through
microchannels or subintimal
planes and luminal re-entry; tip
load 4 gm

Warrior

Guidewire

0.01400 guidewire with 0.00900
diameter tapered distal tip with
hydrophilic coating; penetration
guidewire with 14 gm tip load

Bandit

Guidewire

0.01400 with a 0.00800 diameter
tapered distal tip; polymer
jacketed guidwire with 0.8 gm
tip load; first escalation
guidewire or knuckle wire
subintimal tracking

R350

Guidewire

350 cm 0.01300 externalization
guidewire for retrograde
procedures

confirmation of CTO crossing and guidewire placement in the target
vessel true lumen and absence of in-hospital cardiac death, MI or
repeat target lesion revascularization (major adverse cardiac events,
MACE) among patients undergoing attempted CTO revascularization.
As a primary analysis, the primary endpoint was compared with a performance goal established from pooled analysis of five studies
reporting procedural success in CTO PCI.7–11 Although an investigational guidewire and microcatheter must have been used during
attempted crossing of the CTO, use of additional guidewires were
permitted.
Additional secondary endpoints included the individual components of the composite clinical endpoint through hospital discharge in
addition to technical success (i.e., successful guidewire recanalization),
procedural success according to crossing technique and measures of
resource utilization. Clinical events were assessed during hospital stay
until discharge. Cardiac death was considered as any fatal event not
attributable to a non-cardiac cause. Myocardial infarction was determined per Academic Research Consortium definition criteria12 and
consistent with a predicate CTO registration study.7 Peri-procedural
myocardial infarction was defined as an increase in creatine kinase
MB fraction ≥ 3 times upper normal limit within 48 h of the index procedure. Clinically significant coronary perforation was defined as any
perforation requiring intervention (e.g., prolonged balloon occlusion,
pericardiocentesis, stent graft, or comparable therapy) and/or
resulting in hemodynamic compromise. An independent clinical events
committee adjudicated all adverse events, and study conduct was
supervised by an independent data safety monitoring committee. All
baseline and any additional follow-up angiograms during the study

Purpose

4
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period were reviewed by an independent angiographic core

TABLE 2

Baseline patient clinical and angiographic characteristics

laboratory.

N = 150
Clinical characteristics

2.4

|

Statistical methods

All primary and secondary efficacy and safety endpoints were per-

Age (years)

65.4 ± 10.8

Male gender

84.7 (127)

Diabetes mellitus

32.7 (49)

formed in the intention-to-treat population. Baseline characteristics

Hypertension

91.3 (137)

of study patients were summarized in terms of frequencies and per-

Hyperlipidemia

96.7 (145)

centages for categorical variables and by means with standard devia-

Prior myocardial infarction

48.0 (72)

tions (SD) for continuous variables. Categorical variables were

Angina class III/IV

56.0 (84)

compared by Chi-Square or Fisher's exact test.

Heart failure class III/IV

The primary endpoint was tested using a performance goal for
procedure success, defined as successful guidewire recanalization and
the absence of in-hospital MACE. The estimate of 73.2% for the procedure success endpoint is derived from five historical trials.7–11
Incorporating a 10% statistical delta for hypothesis testing purposes,
the performance goal for the primary endpoint was therefore 63.2%.
With a one-sided type I error rate of 0.05% and 80% statistical power,

8.0 (12)

Prior percutaneous revascularization

51.3 (77)

Prior coronary bypass surgery

32.7 (49)

Prior stroke/TIA

4.7 (7)

Angiographic characteristics
Target vessel
Left main

1.3 (2)

Left anterior descending artery

22.7 (34)

Right coronary artery

63.2

marized in terms of frequencies and percentages for categorical vari-

Left circumflex artery

19.3 (29)

ables and by means with standard deviations for continuous variables.

TIMI 0 flow

99.3 (149)

Moderate/severe calcification

94.7 (142)

a sample size of 135 evaluable patients was required to assess the
performance goal. Secondary efficacy and safety variables were sum-

All analyses were performed with SAS software (version 9.4, SAS
Institute, Cary, NC), R (version 3.2) or other widely accepted statistical

Side branch involvement

36.0 (54)

or graphical software.

Reference vessel diameter (mm)

2.99 ± 0.56

3

RESULTS
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Occlusion length (mm)

46.9 ± 20.5

J CTO Score

1.9 ± 0.9

J CTO Score ≥ 3

24.0 (36)

Collateral circulation

3.1

|

Patient enrollment and characteristics

Baseline clinical and angiographic characteristics are summarized in
Table 2. Among 150 enrolled patients, the prevalence of diabetes was
32.7%; prior MI was documented in 48.0% of patients; and more than
half of patients were characterized as class III/IV angina. Most
patients underwent previous coronary revascularization (prior coronary artery bypass surgery, 32.7%; prior PCI, 51.3%). The average

Ipsilateral

24.0 (36)

Contralateral

62.0 (93)

Bridging

14.0 (21)

Note: Values expressed as mean ± SD or percent (N). Angina and heart
failure severity according to Canadian Cardiovascular Society and New
York Heart Association classification, respectively. TIMI denotes
Thrombolysis in Myocardial Infarction; J CTO, Japanese Chronic Total
Occlusion; TIA, transient ischemic attack.

(mean ± SD) occlusion length was 46.9 ± 20.5 mm, and average Japan
CTO (J-CTO) score was 1.9 ± 0.9. More than half of the target lesions
(56.7%) were located in the right coronary artery, and moderate/

for procedural success, the study primary endpoint was met (lower

severe calcification was identified in nearly all cases (94.7%).

one-sided 95% confidence interval [CI] boundary 68.9%, P = 0.001).
Among patients with in-hospital adverse events, cardiac death
occurred in 1 patient (0.7%), and rates of MI and target lesion revascu-

3.2

|

Procedural and clinical outcomes

larization were 18.0% and 0.7%, respectively (Table 4). All MI events
were peri-procedural (i.e., no spontaneous events), and MI defined as

Technical success was observed in 94.7% (142/150) of cases, and in-

CK MB > 10 times upper normal limit occurred in 6.0% of patients. As

hospital MACE occurred in 19.3% (29/150) of patients (Tables 3 and

a prespecified analysis by this modified MI definition, in-hospital

4). Procedure success was therefore achieved in 75.3% (113/150) of

MACE and procedural success rates were 7.3% and 87.3%, respec-

patients. Final TIMI grade III and II flow was achieved in 89.3% and

tively. No major adverse events were reported from hospital discharge

4.0% of cases, respectively. Final TIMI grade III flow and a percent

through 30 days.

residual stenosis < 30% was observed in 80.0% of cases (120/150).

Coronary perforation was characterized according to both angio-

Compared with the guidewire performance goal endpoint of 63.2%

graphic criteria13 and protocol definition. Among 21 angiographically

5
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TABLE 3

Procedural results

A total of 1022 guidewires were reported to facilitate or cross
N = 150

guidewires (44.6%). The mean number of 4.8 ± 2.8 study guidewires

Vascular access
Femoral

41.3 (62)

Radial

8.7 (13)

Femoral and radial

the CTO: 566 study guidewires (55.4%) and 456 non-study

50.0 (75)

were used per subject, and a mean number of 5.1 ± 3.3 all guidewires
(study devices and non-study devices) were used per subject. Reasons
for non-study guidewires cited were crossing difficulty and physician
preference. Overall, Spectre was used in 86.0% of patients; Raider

Stent length (mm)

61.7 ± 23.6

guidewire, 68.0%; Bandit guidewire, 45.3%; Warrior guidewire,

Final TIMI 3 flow

89.3 (134)

23.3%; and R350 guidewire 26.0%. Study guidewires were the final

Clinically significant perforationa

10.7 (16)

crossing guidewire in 60 subjects (40%), most commonly using the

Procedure time (minutes)

149.0 ± 90.9

Raider guidewire in 18% of subjects.

Contrast volume (mL)

205.2 ± 94.8

A Turnpike microcatheter was used in all cases (Turnpike stan-

Radiation dose (mGy)

2220 ± 1608

dard, 22.0%; Turnpike LP, 56.7%; Spiral, 62.7%; Gold, 0.7%), and the

Procedural success

75.3 (113)

GuideLiner and TrapLiner guide extensions were utilized in 16.0% and

Technical success

94.7 (142)

55.3% of cases, respectively.
Regarding procedural method, 54.0% of procedures employed

Procedural success by crossing strategy
Antegrade

85.2 (69/81)

Retrograde

50.0 (1/2)

Combined antegrade and retrograde

64.2 (43/67)

Note: Values expressed as percent (N) or mean ± SD.
a
Clinically significant perforation defined as any perforation resulting in
hemodynamic instability and/or requiring intervention.

antegrade only crossing techniques; 44.7% applied combined
antegrade and retrograde techniques; and 1.3% involved retrograde
crossing only. Reverse controlled antegrade-retrograde subintimal
tracking (CART) represented 14.0% of procedures, and antegrade dissection/re-entry with StingRay catheters occurred in 11.3% of cases.
Among retrograde cases, an antegrade guide catheter extension was
used in 12 subjects. Procedural success by method is listed in Table 3.
Technical success for antegrade only methods was 95.1% (77/81

TABLE 4

cases); for retrograde only methods, 100.0% (2/2 cases); and for com-

In-hospital clinical outcomes
N = 150

Death
Cardiac Death

bined antegrade/retrograde methods, 94.0% (63/67 cases). Major
adverse cardiac events during hospitalization were more common

0.7 (1)

among procedures involving a retrograde strategy compared with

0.7 (1)

antegrade-only procedures (30.4% [21/69] versus 9.9% [8/81],
P = 0.002), a difference driven by protocol-defined MI (retrograde

MI
CK MB ≥3X ULN

18.0 (27)

29.0% [20/69], versus antegrade 86% [7/81], P = 0.0014). Using a

CK MB ≥10X ULN

6.0 (9)

modified definition of MI defined as CK MB >10 times upper normal

0.7 (1)

limit, no significant differences were observed between antegrade

Target lesion revascularization
MACE

and retrograde procedures (retrograde 8.7% [6/69], versus antegrade

a

Using CK MB ≥3X ULN

19.3 (29)

Using CK MB ≥10X ULN

7.3 (11)

Note: Values expressed as percent (N).
a
Major adverse cardiac events (MACE) included myocardial infarction (MI)
defined as creatine kinase myocardial band (CK MB) ≥3X upper limit of
normal (ULN) as the primary analysis.

3.7% [3/81], P = 0.30).
The mean total procedure time was 149 ± 91 min. The average
contrast volume per procedure was 205 ± 95 mL, and the mean radiation dose was 2220 ± 1608 mGy.

4
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determined perforations, 10 and 8 events were classified as type II and

In a registration study evaluating specialized guidewires, microcatheters

III, respectively. Clinically significant coronary perforation occurred in

and guide catheter extensions for CTO PCI, successful guidewire recanali-

16 (10.7%) patients (Table 2). Among these cases, 10 events were adju-

zation was achieved in 94.7% of patients, and overall procedural success

dicated as unrelated to a study device. Covered stent implantation

per protocol definition was 73.5%, achieving statistical significance com-

and/or pericardiocentesis was performed in eight cases, and the

pared with a prespecified performance goal established from pooled anal-

remaining cases were resolved with prolonged balloon occlusion and

ysis of prior studies reporting procedural success in CTO PCI. Despite a

one instance of vessel branch embolization. Despite the occurrence of

high coronary perforation rate similar to other contemporary CTO

perforation, technical success was achieved in 12/16 (75.0%) cases, yet

studies,7,14,15 in-hospital major adverse events were principally related to

procedural success was reported for 5/16 (31.3%) patients. For the one

periprocedural biomarker elevation. Altogether, these results inform both

episode of cardiac death, coronary perforation occurred followed by

CTO procedural strategy applying contemporary technique and devices

covered stent placement and subacute stent thrombosis.

but also the opportunity for advancement of procedural safety.

6
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Despite remarkable progress in complex percutaneous revasculari-

biomarker elevation and were not associated with clinically manifest

zation, chronically occluded coronary arteries represent a persistent

events from discharge through 30-day follow-up. The MI rate may

challenge regarding patient selection, interventional technique and like-

also have been influenced by a high prevalence of retrograde proce-

lihood of procedural success. For more than a decade—and despite

dures that have been associated with increased procedural-related

increasing performance of attempted CTO PCI—advances in procedural

adverse events.16,20,23,24 Criteria for MI in CTO trials have been

success have been limited, and measurable improvement in safety has

proposed,25,26 and protocol-specific definitions of MI may substan-

been offset by increasing case complexity. In part highlighting the vari-

tially influence event rates, as in this trial example. As a prespecified

ability in operator experience, case selection and availability of

analysis, when measured by an alternative Society of Coronary Angi-

advanced device technology, procedural success rates have ranged from

ography and Interventions definition of peri-procedural MI,27 the in-

60% to more than 90%1,16–18 among contemporary series. In the pre-

hospital MACE and procedural success rates were 7.3% and 87.3%,

sent study with limited clinical and angiographic exclusion criteria, PCI

respectively.

employing advanced guidewire technique and procedural strategy

The incidence of coronary perforation is representative of CTO

resulted in a guidewire crossing rate that exceeds historical standards.

lesion complexity, high-risk procedural technique and the specialized

Equally remarkable is the use of procedural strategies in which these

design of guidewires. By similar criteria, clinically significant coronary

CTO-specific technologies were applied, including a very high preva-

perforation was reported in 8.0%, 5.2%, and 4.3% of procedures in

lence of retrograde procedures representing approximately one-half of

the Asahi CTO, PERSPECTIVE, and OPEN CTO studies, respec-

cases. The favorable success rates achieved despite extensive lesion

tively.7,14,15 In the present study, among 16 (10.7%) clinically signifi-

length, severe calcification and a high prevalence of prior coronary

cant perforations that required intervention and/or resulted in

bypass surgery challenge historical perception that successful guidewire

hemodynamic instability, eight cases required covered stent implanta-

crossing is inversely related to lesion complexity.

tion and/or pericardiocentesis, and one event death occurred follow-

Reflecting the complexity of both anatomy and procedural strat-

ing covered stent thrombosis. Although successful guidewire crossing

egy, performance of CTO PCI defines the need for an “interven-

of the CTO was successful in 75.0% of these cases, the occurrence of

tional toolbox” that features an array of enabling device

procedural success was considerably lower compared to cases with-

technologies. Because coronary guidewires vary in numerous ways

out significant perforation (31.3% vs. 80.0%, P = 0.0003) related to a

that affect device performance and procedural outcomes, the dedi-

higher incidence of major adverse events. These observations under-

cated purpose of a CTO-specific guidewire may be to penetrate the

score the need not only for operator proficiency in achieving vessel

proximal cap occlusion, navigate collateral channels, facilitate sub-

patency but also regarding skillsets for complication management. The

intimal tracking, or enable true lumen re-entry (Table 1). Representa-

persistently high rate of coronary perforation and its association with

tive of both the technical complexity and intended design, an

both early and late adverse outcome28,29 temper the advancement of

average (±SD) of 4.8 ± 2.8 study guidewires were used per case in

technical and procedural success and inform the need to refine strate-

the present study. As an additional enabling technology, at least one

gies that promote procedural safety.

microcatheter was utilized in all study procedures, and similar to

A limitation of this study is that as a non-randomized design, mea-

guidewires, the microcatheter designs have been further modified to

sured, or unmeasured confounders may have influenced the comparison

match a specific objective such as navigation though tortuous or

of outcomes with a performance goal derived from a pooled analysis of

small caliber collateral channels or crossing though calcified, resis-

prior CTO trials reporting procedural outcomes. In addition, the system-

tant occlusive plaque (Table 1). Guide catheter extensions provide

atic ascertainment of peri-procedural biomarkers for all patients and a

not only advanced support for guidewire crossing but also enable

more conservative definition of MI applied in this study limits comparison

device delivery and exchange, and in some instances facilitate retro-

with historical studies but would be expected to bias against the present

grade guidewire recanalization (Table 1).

19

As a unique guide exten-

study results. As a registration trial with FDA oversight, this definition

sion design, the TrapLiner device also enables device exchange over

was required to maintain comparability with previous studies evaluating

a 180–190 cm guidewire without the need for guidewire exchange,

CTO-specific technologies.7,8 Also, as a study intended to evaluate the

guidewire extension or introduction of an additional trapping angio-

utility and effectiveness of guidewire and catheter technologies, clinical

plasty balloon within the guiding catheter.

follow-up was also limited to 30 days, thereby limiting insight to late-term

Despite a high rate of technical success in the present study, the

outcomes that may be related to early procedural failure or complica-

lower procedural success rate was principally driven by the incidence

tions.29,30 Finally, these results were observed among centers identified

of protocol-defined peri-procedural MI. In previous reports, rates of

with expertise in CTO PCI and therefore may not be generalizable to a

procedural-related MI have ranged from 8.6% to 18.3% when apply-

broader, less selected group of interventional operators.

ing similar criteria.7,20–22 However, comparison of MI rates (and
therefore also procedural success) with most CTO observational
studies should be done with caution given the absence of protocol-

5
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mandated, systematic biomarker ascertainment, and subsequent
underreporting of procedural-related events. Importantly, all MI

Complementing the evolution of procedural technique and strategy in

events in the current study were related to peri-procedural

CTO PCI, the advancement of dedicated guidewire and catheter

7
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technologies enable the highest observed success rates compared
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